RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer.
The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem.
RenovoGem utilizes the RenovoRx proprietary RenovoTAMP therapy platform. It provides targeted intra-arterial delivery of FDA-approved chemotherapy, known as gemcitabine. This treats LAPC following stereotactic body radiation therapy (SBRT). The pressure-mediated delivery technology delivers the therapy locally, across the arterial wall to bathe tumor tissue in chemotherapy.
Get the full story at our sister site, Drug Delivery Business News.